Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03399981 · ClinicalTrials.gov registry record
Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 80,327
- Enrollment target
NCT03399981 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 80,327 participants.
The verdict
NCT03399981 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 80,327 participants
- Enrollment target
Study Summary
The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate). Researchers will also look to estimate the incidence of other serious opportunistic infections among patients who switch to Tysabri from newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs (interferon beta and glatiramer acetate)
Interventions
- BIOLOGICAL Tysabri
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80,327 participants |
| Start Date | 2017-06-01 |
| Est. Completion | 2023-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03399981
The ClinicalTrials.gov registry entry for NCT03399981 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80,327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tysabri is the first listed.
NCT03399981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03399981 about?
NCT03399981 is a clinical study titled "Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries". The primary purpose of this study is to estimate the incidence of progressive multifocal leukoencephalopathy (PML) among patients who switched to Tysabri from disease modifying therapies (DMTs), including newer DMTs (including fingolimod, dimethyl fumarate and teriflunomide) and the established DMTs...
What is the current status of trial NCT03399981?
This trial is currently completed. The enrollment target is 80,327 participants. The study started on 2017-06-01. Estimated completion is 2023-12-31.
What interventions are being tested in trial NCT03399981?
The interventions under investigation include: Tysabri (BIOLOGICAL).
Who is sponsoring clinical trial NCT03399981?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.